Alkermes plays up responses in mucosal melanoma, but those hoping for an IL-2 renaissance might be disappointed.
The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Early signs suggest that Alkermes might have found a therapeutic window with its IL-2-targeting agent, ALKS 4230.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.